Jonathan M. Ostrem

Chemical biology, Ras biology

Kevan Michael Shokat	grad student	2009-2013	UCSF
(Development of an irreversible mutant-specific inhibitor of oncogenic K-Ras G12C.)

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Luo J, Ostrem J, Pellini B, et al. (2022) Overcoming -Mutant Lung Cancer. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 42: 1-11
Ostrem JM, Shokat KM. (2016) Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nature Reviews. Drug Discovery. 15: 771-785
Schroeder CM, Ostrem JM, Hertz NT, et al. (2014) A Ras-like domain in the light intermediate chain bridges the dynein motor to a cargo-binding region. Elife. 3: e03351
Chen L, Shu Y, Liang X, et al. (2014) OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proceedings of the National Academy of Sciences of the United States of America. 111: 9983-8
Ostrem JM, Peters U, Sos ML, et al. (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 503: 548-51
Ostrem JM, Peters U, Ren P, et al. (2013) Abstract LB-311: Development of mutant-specific small molecule inhibitors of K-Ras. Cancer Research. 73
Ostrem JM, Peters U, Sos ML, et al. (2013) Abstract PL04-03: Selective inhibition of K-Ras G12C through allosteric control of GTP affinity and effector interactions. Molecular Cancer Therapeutics. 12